rofecoxib has been researched along with Chronic Disease in 29 studies
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "We determine the effects of treatment with rofecoxib and placebo in patients with chronic prostatitis." | 9.10 | A randomized, placebo controlled, multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis. ( Bach, M; Drisko, J; Farrington, J; Gittelman, M; Krupa, D; Malek, G; Moon, T; Nickel, JC; Pearson, J; Pontari, M, 2003) |
| "Two replicate, 4-week, randomized, double-blind, placebo-controlled, trials of rofecoxib 25 and 50 mg versus placebo for chronic low back pain." | 9.10 | Efficacy and safety of rofecoxib in patients with chronic low back pain: results from two 4-week, randomized, placebo-controlled, parallel-group, double-blind trials. ( Borenstein, D; Bozalis Rodgers, D; Coleman, S; Fisher, C; Gertz, BJ; Gimbel, J; Ju, WD; Katz, N; Krupa, DA; Nabizadeh, S; Sperling, RS, 2003) |
| "We determine the effects of treatment with rofecoxib and placebo in patients with chronic prostatitis." | 5.10 | A randomized, placebo controlled, multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis. ( Bach, M; Drisko, J; Farrington, J; Gittelman, M; Krupa, D; Malek, G; Moon, T; Nickel, JC; Pearson, J; Pontari, M, 2003) |
| "Two replicate, 4-week, randomized, double-blind, placebo-controlled, trials of rofecoxib 25 and 50 mg versus placebo for chronic low back pain." | 5.10 | Efficacy and safety of rofecoxib in patients with chronic low back pain: results from two 4-week, randomized, placebo-controlled, parallel-group, double-blind trials. ( Borenstein, D; Bozalis Rodgers, D; Coleman, S; Fisher, C; Gertz, BJ; Gimbel, J; Ju, WD; Katz, N; Krupa, DA; Nabizadeh, S; Sperling, RS, 2003) |
| "We know from adult randomised controlled trials that some NSAIDs, such as ibuprofen, naproxen, and aspirin, can be effective in certain chronic pain conditions." | 4.95 | Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents. ( Anderson, B; Cooper, TE; Eccleston, C; Fisher, E; Wilkinson, NM, 2017) |
| "Substituted thiazoles with different structural features were synthesized and screened for their anti-inflammatory activity in acute carrageenin induced rat paw edema model and chronic formalin induced rat paw edema model." | 3.74 | 2-Amino-5-thiazolyl motif: a novel scaffold for designing anti-inflammatory agents of diverse structures. ( Franklin, PX; Nivsarkar, M; Padh, H; Pillai, AD; Rathod, PD; Sudarsanam, V; Vasu, KK; Yerande, S, 2008) |
| " In a chronic model, by acetic acid-induced gastric ulcers, COX-2 was expressed at 7 days and was also associated with PGE(2) increase." | 3.73 | COX expression and PGE(2) and PGD(2) production in experimental acute and chronic gastric lesions. ( Alarcón de la Lastra, C; Bruseghini, L; Manuel Herrerias, J; Motilva, V; Sánchez-Fidalgo, S, 2005) |
| " Comparisons were made between patients taking rofecoxib and those taking either placebo, naproxen (an NSAID with near-complete inhibition of platelet function throughout its dosing interval), or another nonselective NSAIDs used in the development program (diclofenac, ibuprofen, and nabumetone)." | 2.41 | Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. ( Barr, E; Gertz, BJ; Konstam, MA; Reicin, A; Shapiro, D; Sperling, RS; Weir, MR, 2001) |
| "Diagnostic delay and misdiagnoses of unilateral headaches, as illustrated by this case, shows the clinical controversies and difficulties in diagnosing and treating this condition." | 1.37 | [A woman with unilateral headache]. ( Bekkelund, SI; Müller, KI, 2011) |
| " Following dosing of CFA-injected rats with rofecoxib (Vioxx) or paracetamol, there was a significant decrease in the number of ipsilateral CGRP-IR small and medium DRG neurones in rofecoxib- but not paracetamol-treated rats." | 1.34 | Changes in dorsal root ganglion CGRP expression in a chronic inflammatory model of the rat knee joint: differential modulation by rofecoxib and paracetamol. ( Bountra, C; Chessell, IP; Day, NC; Staton, PC; Wilson, AW, 2007) |
| " Ibuprofen, a non-selective COX inhibitor, at 5mg/kg, orally dosed three times a day for 5 days did not significantly affect the PWTs in CCI rats." | 1.34 | GW406381, a novel COX-2 inhibitor, attenuates spontaneous ectopic discharge in sural nerves of rats following chronic constriction injury. ( Chessell, IP; Martindale, JC; Reeve, AJ; Spanswick, D; Zhao, FY, 2007) |
| "In indomethacin and rofecoxib-treated gerbils, the following results were obtained in H pylori-infected group vs H pylori-eradicated group respectively: hyperplasia area of the stomach (mm2): 82." | 1.33 | Eradication of Helicobacter pylori significantly reduced gastric damage in nonsteroidal anti-inflammatory drug-treated Mongolian gerbils. ( Chang, CC; Chen, SH; Fang, CL; Hsieh, CR; Lien, GS; Lou, HY; Pan, S, 2005) |
| "Rofecoxib was used for eight acute haemarthrosis, four target joints, seven cases of synovitis and 12 episodes of pain." | 1.33 | Rofecoxib as adjunctive therapy for haemophilic arthropathy. ( Nugent, DJ; Rattray, B; Young, G, 2005) |
| "Treatment with rofecoxib significantly decreased these elevations except on day 4 of the study." | 1.33 | Increased expression of cyclooxygenase-2 (COX-2) in radiation-induced small bowel injury in rats. ( Can, B; Cengiz, M; Gencturk, S; Gocmen, E; Keskek, M; Kilic, M; Koc, M; Okten, RM, 2006) |
| "In vehicle-treated rats, gastric ulcers healed progressively and at day 14 the healing was completed, accompanied by a significant rise in the GBF at ulcer margin." | 1.31 | Classic NSAID and selective cyclooxygenase (COX)-1 and COX-2 inhibitors in healing of chronic gastric ulcers. ( Brzozowski, T; Drozdowicz, D; Hahn, EG; Konturek, PC; Konturek, SJ; Pajdo, R; Ptak, A; Sliwowski, Z, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 26 (89.66) | 29.6817 |
| 2010's | 3 (10.34) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Franklin, PX | 1 |
| Pillai, AD | 1 |
| Rathod, PD | 1 |
| Yerande, S | 1 |
| Nivsarkar, M | 1 |
| Padh, H | 1 |
| Vasu, KK | 1 |
| Sudarsanam, V | 1 |
| Giblin, GM | 1 |
| Billinton, A | 1 |
| Briggs, M | 1 |
| Brown, AJ | 1 |
| Chessell, IP | 4 |
| Clayton, NM | 1 |
| Eatherton, AJ | 1 |
| Goldsmith, P | 1 |
| Haslam, C | 1 |
| Johnson, MR | 1 |
| Mitchell, WL | 1 |
| Naylor, A | 1 |
| Perboni, A | 1 |
| Slingsby, BP | 1 |
| Wilson, AW | 3 |
| Eccleston, C | 1 |
| Cooper, TE | 1 |
| Fisher, E | 1 |
| Anderson, B | 1 |
| Wilkinson, NM | 1 |
| Kumar, A | 1 |
| Kumari, B | 1 |
| Kumar, P | 1 |
| Müller, KI | 1 |
| Bekkelund, SI | 1 |
| Jeske, AH | 1 |
| Nickel, JC | 1 |
| Pontari, M | 1 |
| Moon, T | 1 |
| Gittelman, M | 1 |
| Malek, G | 1 |
| Farrington, J | 1 |
| Pearson, J | 1 |
| Krupa, D | 1 |
| Bach, M | 1 |
| Drisko, J | 1 |
| Boehncke, WH | 1 |
| Ludwig, RJ | 1 |
| Zollner, TM | 1 |
| Ochsendorf, F | 1 |
| Kaufmann, R | 1 |
| Gibbs, BF | 1 |
| Spiegel, BM | 1 |
| Targownik, L | 1 |
| Dulai, GS | 1 |
| Gralnek, IM | 1 |
| Giles, LG | 1 |
| Muller, R | 1 |
| Katz, N | 1 |
| Ju, WD | 1 |
| Krupa, DA | 1 |
| Sperling, RS | 2 |
| Bozalis Rodgers, D | 1 |
| Gertz, BJ | 2 |
| Gimbel, J | 1 |
| Coleman, S | 1 |
| Fisher, C | 1 |
| Nabizadeh, S | 1 |
| Borenstein, D | 1 |
| Siow, HC | 1 |
| Ashton, D | 1 |
| Kim, P | 1 |
| Griffiths, N | 1 |
| Beran, R | 1 |
| Jayr, C | 1 |
| Tran, F | 1 |
| Boggie, DT | 1 |
| Delattre, ML | 1 |
| Schaefer, MG | 1 |
| Morreale, AP | 1 |
| Plowman, BK | 1 |
| Chang, CC | 1 |
| Chen, SH | 1 |
| Lien, GS | 1 |
| Lou, HY | 1 |
| Hsieh, CR | 1 |
| Fang, CL | 1 |
| Pan, S | 1 |
| Motilva, V | 1 |
| Alarcón de la Lastra, C | 1 |
| Bruseghini, L | 1 |
| Manuel Herrerias, J | 1 |
| Sánchez-Fidalgo, S | 1 |
| Rattray, B | 1 |
| Nugent, DJ | 1 |
| Young, G | 1 |
| Medhurst, SJ | 1 |
| Dixon, CI | 1 |
| Bontoft, NC | 1 |
| Winyard, LA | 1 |
| Brackenborough, KT | 1 |
| De Alba, J | 1 |
| Clarke, CJ | 1 |
| Gunthorpe, MJ | 1 |
| Hicks, GA | 1 |
| Bountra, C | 2 |
| McQueen, DS | 1 |
| Klasser, GD | 1 |
| Epstein, J | 1 |
| Staton, PC | 1 |
| Day, NC | 1 |
| Dimitrakov, JD | 1 |
| Kaplan, SA | 1 |
| Kroenke, K | 1 |
| Jackson, JL | 1 |
| Freeman, MR | 1 |
| Keskek, M | 1 |
| Gocmen, E | 1 |
| Kilic, M | 1 |
| Gencturk, S | 1 |
| Can, B | 1 |
| Cengiz, M | 1 |
| Okten, RM | 1 |
| Koc, M | 1 |
| Zhao, FY | 1 |
| Spanswick, D | 1 |
| Martindale, JC | 1 |
| Reeve, AJ | 1 |
| Brzozowski, T | 1 |
| Konturek, PC | 1 |
| Konturek, SJ | 1 |
| Sliwowski, Z | 1 |
| Pajdo, R | 1 |
| Drozdowicz, D | 1 |
| Ptak, A | 1 |
| Hahn, EG | 1 |
| Konstam, MA | 1 |
| Weir, MR | 1 |
| Reicin, A | 1 |
| Shapiro, D | 1 |
| Barr, E | 1 |
| Kessenich, CR | 1 |
| Block, SH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Trigger Point Dry Needling vs Trigger Point Dry Needling With Intramuscular Electrical Stimulation for the Treatment of Sub-acute and Chronic Low Back Pain in a Military Population: A Randomized Crossover Design[NCT03539588] | 30 participants (Actual) | Interventional | 2017-04-12 | Completed | |||
| Changes in Pressure Pain Thresholds and Basal Electromyographic Activities Following Spinal Mechanical Manipulation in Asymptomatic Subjects[NCT01469533] | 30 participants (Actual) | Interventional | 2011-07-31 | Completed | |||
| Genetic Studies of Urologic Chronic Pelvic Pain Syndrome[NCT00675298] | 300 participants (Anticipated) | Observational | 2006-01-31 | Completed | |||
| Diagnostic Challenges in IC (and Male CPPS)[NCT00672087] | 1,000 participants (Anticipated) | Observational | 2003-09-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for rofecoxib and Chronic Disease
| Article | Year |
|---|---|
Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Juvenile; Arthritis, Rheumatoid; Asp | 2017 |
Selecting new drugs for pain control: evidence-based decisions or clinical impressions?
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Clinical Trials as Topic; C | 2002 |
The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celecoxib; | 2003 |
[Analgesic effects of cyclooxygenase 2 inhibitors].
Topics: Acute Disease; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chronic Disease; Cycl | 2004 |
Nonsteroidal anti-inflammatory drugs: confusion, controversy and dental implications.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chronic Disease; Clinical Trials | 2005 |
Management of chronic prostatitis/chronic pelvic pain syndrome: an evidence-based approach.
Topics: Adrenergic alpha-Antagonists; Adult; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; | 2006 |
Management of chronic prostatitis/chronic pelvic pain syndrome: an evidence-based approach.
Topics: Adrenergic alpha-Antagonists; Adult; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; | 2006 |
Management of chronic prostatitis/chronic pelvic pain syndrome: an evidence-based approach.
Topics: Adrenergic alpha-Antagonists; Adult; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; | 2006 |
Management of chronic prostatitis/chronic pelvic pain syndrome: an evidence-based approach.
Topics: Adrenergic alpha-Antagonists; Adult; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; | 2006 |
Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib.
Topics: Aged; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascu | 2001 |
Cyclo-oxygenase 2 inhibitors: an important new drug classification.
Topics: Acute Disease; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Celecoxib; Chr | 2001 |
4 trials available for rofecoxib and Chronic Disease
| Article | Year |
|---|---|
A randomized, placebo controlled, multicenter study to evaluate the safety and efficacy of rofecoxib in the treatment of chronic nonbacterial prostatitis.
Topics: Adult; Aged; Chronic Disease; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Double- | 2003 |
Chronic spinal pain: a randomized clinical trial comparing medication, acupuncture, and spinal manipulation.
Topics: Acupuncture Therapy; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chronic Disease; Double-Bli | 2003 |
Chronic spinal pain: a randomized clinical trial comparing medication, acupuncture, and spinal manipulation.
Topics: Acupuncture Therapy; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chronic Disease; Double-Bli | 2003 |
Chronic spinal pain: a randomized clinical trial comparing medication, acupuncture, and spinal manipulation.
Topics: Acupuncture Therapy; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chronic Disease; Double-Bli | 2003 |
Chronic spinal pain: a randomized clinical trial comparing medication, acupuncture, and spinal manipulation.
Topics: Acupuncture Therapy; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chronic Disease; Double-Bli | 2003 |
Efficacy and safety of rofecoxib in patients with chronic low back pain: results from two 4-week, randomized, placebo-controlled, parallel-group, double-blind trials.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Cyclooxygenase In | 2003 |
Therapeutic interchange involving replacement of rofecoxib or celecoxib with valdecoxib.
Topics: Aged; Aged, 80 and over; Arthritis, Rheumatoid; Celecoxib; Chronic Disease; Cost Savings; Cyclooxyge | 2004 |
17 other studies available for rofecoxib and Chronic Disease
| Article | Year |
|---|---|
2-Amino-5-thiazolyl motif: a novel scaffold for designing anti-inflammatory agents of diverse structures.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Chronic Disease; Cyclooxygenase Inhib | 2008 |
Discovery of 1-[4-(3-chlorophenylamino)-1-methyl-1H-pyrrolo[3,2-c]pyridin-7-yl]-1-morpholin-4-ylmethanone (GSK554418A), a brain penetrant 5-azaindole CB2 agonist for the treatment of chronic pain.
Topics: Aminopyridines; Animals; Aza Compounds; Brain; Cell Line; CHO Cells; Chronic Disease; Cricetinae; Cr | 2009 |
Protective effects of selective and non-selective cyclooxygenase inhibitors in an animal model of chronic stress.
Topics: Animals; Anxiety; Catalase; Chronic Disease; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; | 2010 |
[A woman with unilateral headache].
Topics: Chronic Disease; Cyclooxygenase 2 Inhibitors; Delayed Diagnosis; Diagnosis, Differential; Disease Pr | 2011 |
The selective cyclooxygenase-2 inhibitor rofecoxib may improve the treatment of chronic idiopathic urticaria.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Cyclooxygenase Inhibitors; Female; | 2003 |
Summaries for patients. The cost-effectiveness of cyclooxygenase-2 inhibitors for treating chronic arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Chronic Disease; Cost-Ben | 2003 |
Seasonal episodic paroxysmal hemicrania responding to cyclooxygenase-2 inhibitors.
Topics: Aged; Chronic Disease; Cluster Headache; Creatinine; Cyclooxygenase Inhibitors; Female; Humans; Indo | 2004 |
Cognitive decline with chronic meningitis secondary to a COX-2 inhibitor.
Topics: Aged; Chronic Disease; Cognition Disorders; Cyclooxygenase 2; Female; Humans; Isoenzymes; Lactones; | 2004 |
Eradication of Helicobacter pylori significantly reduced gastric damage in nonsteroidal anti-inflammatory drug-treated Mongolian gerbils.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Chronic Diseas | 2005 |
COX expression and PGE(2) and PGD(2) production in experimental acute and chronic gastric lesions.
Topics: Acetic Acid; Acute Disease; Animals; Chronic Disease; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxyge | 2005 |
Rofecoxib as adjunctive therapy for haemophilic arthropathy.
Topics: Acute Disease; Adjuvants, Pharmaceutic; Administration, Oral; Adolescent; Adult; Anti-Inflammatory A | 2005 |
An animal model of chronic inflammatory pain: pharmacological and temporal differentiation from acute models.
Topics: Animals; Arthritis; Chronic Disease; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Freund's A | 2006 |
Changes in dorsal root ganglion CGRP expression in a chronic inflammatory model of the rat knee joint: differential modulation by rofecoxib and paracetamol.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Arthritis, Experimental; Calcitonin Gene-Related P | 2007 |
Increased expression of cyclooxygenase-2 (COX-2) in radiation-induced small bowel injury in rats.
Topics: Acute Disease; Animals; Apoptosis; Chronic Disease; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; D | 2006 |
GW406381, a novel COX-2 inhibitor, attenuates spontaneous ectopic discharge in sural nerves of rats following chronic constriction injury.
Topics: Action Potentials; Animals; Chronic Disease; Constriction, Pathologic; Cyclooxygenase 2 Inhibitors; | 2007 |
Classic NSAID and selective cyclooxygenase (COX)-1 and COX-2 inhibitors in healing of chronic gastric ulcers.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chronic Disease; Cyclooxygenase 1; Cycloo | 2001 |
Chronic sinusitis with rofecoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Humans; Lactones; Male; Middle Aged; Sinus | 2002 |